<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000299584"><TermName>semaxanib</TermName><TermPronunciation>(seh-MAK-suh-nib)</TermPronunciation><TermDefinition><DefinitionText>A substance that has been studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and tyrosine kinase inhibitors. Also called SU5416.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000710222" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;semaxanib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000710221" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;semaxanib&quot;" language="es" id="_4"/><SpanishTermName>semaxanib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del cáncer. Es un tipo de inhibidor de la angiogénesis e inhibidor de la tirosina cinasa. También se llama SU5416.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2003-03-24</DateFirstPublished><DateLastModified>2005-05-26</DateLastModified></GlossaryTerm>
